Figure 3.

Targeted disruptions of DBC1 or SIRT1 reduced liver cancer cell viability. HepG2 (A) and SNU-182 (B) cells were transfected with siRNAs targeting SIRT1 or DBC1 (50 or 200 nM), and then treated with 20 μM of etoposide for 12 h. Cell viabilities were determined by MTT assay as described in Materials and methods. Data are presented as means ± standard deviation of three experiments (unpaired Student’s t-test, ^*P<0.05 vs. si-control). SIRT1, silent mating type information regulation 2 homolog 1; DBC1, deleted in breast cancer-1.